Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.
about
Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesRefractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.A stepwise approach for the management of poisoning with extracorporeal treatments.ABO-Incompatible Adult Living Donor Liver Transplantation Under the Desensitization Protocol With Rituximab.Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation.Pro: High dose of therapeutic plasma exchange-mind the gap!Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future?[Role of plasmapheresis and immunoadsorption in salvage therapy of rheumatological diseases].
P2860
Q26776308-5609D434-2397-4A48-BC66-D896D9BCA1EBQ33410868-71268D60-3B30-48CE-9699-09CF43297BFBQ33416588-77E044D6-09D3-46EC-9416-AE0C45D1C2C3Q33427885-6D453FD3-4C2F-49B1-9CB3-01BBE667DAACQ38201803-EE6372BC-1F06-445B-AEB8-F96261FC84C8Q38422411-98EF1ECB-694E-43A4-ACCB-E6274AF7665CQ39409394-DB1BD555-1276-4E9B-8296-C67E1A5961F0Q47741998-AD4738CC-F553-485E-B035-3FCC62576891Q47800187-BCDE9FF3-5375-4963-AE6D-8BFAA2D1CFEDQ51733829-C2ACB5D0-3D6E-43D5-B4AF-6C40C3C9AAA4
P2860
Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Population pharmacokinetics of ...... ith antibody-mediated disease.
@en
Population pharmacokinetics of ...... ith antibody-mediated disease.
@nl
type
label
Population pharmacokinetics of ...... ith antibody-mediated disease.
@en
Population pharmacokinetics of ...... ith antibody-mediated disease.
@nl
prefLabel
Population pharmacokinetics of ...... ith antibody-mediated disease.
@en
Population pharmacokinetics of ...... ith antibody-mediated disease.
@nl
P2093
P2860
P50
P356
P1476
Population pharmacokinetics of ...... with antibody-mediated disease
@en
P2093
Anaïs Grand
Antoine Huart
Chantal Le Guellec
Frédérique Haberer
Jacques Pourrat
Lionel Rostaing
Thierry Lafont
P2860
P304
P356
10.1111/BCP.12098
P407
P577
2013-11-01T00:00:00Z